Last updated July 18, 2026
Key finding
The least squares mean change from baseline in HbA1c at Week 16 was -1.79% in the SITA+MET+GLIM group.
This study evaluated the efficacy and safety of a triple fixed-dose combination of sitagliptin, metformin, and glimepiride in Indian patients with uncontrolled Type 2 diabetes, finding significant reductions in HbA1c levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy and safety of a triple fixed-dose combination of sitagliptin, metformin, and glimepiride in Indian patients with uncontrolled Type 2 diabetes, finding significant reductions in HbA1c levels.
This study highlights the potential benefits of a triple fixed-dose combination therapy in managing Type 2 diabetes, particularly in populations with uncontrolled blood sugar levels. Improved glycemic control can lead to better long-term health outcomes for patients, reducing the risk of diabetes-related complications. The findings suggest that such combination therapies could be a valuable option for clinicians treating patients with Type 2 diabetes.
The study was limited to Indian patients, which may affect generalizability. Sample sizes in both groups may limit the robustness of the findings. The study duration of 16 weeks may not capture long-term effects.
Published in
Publication details and source links for this paper.
Rakesh S, Ambanna G, Manish KS, et al. Efficacy and safety of a triple fixed-dose combination of sitagliptin, metformin, and glimepiride in Indian patients with uncontrolled Type 2 diabetes. Diabetes, Obesity & Metabolism. 2026;28(7):6207-6216. doi:10.1111/dom.70778
The SITA+MET+GLIM group showed a mean HbA1c reduction of -1.79% (p=0.0001).
32.1% of patients in the SITA+MET+GLIM group achieved HbA1c < 7% (p=0.0001).
The co-administration group had a mean HbA1c reduction of -1.27% (p=0.0001).
12.6% of patients in the co-administration group achieved HbA1c < 7% (p=0.0001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Metformin + glimepiride and Adverse events incidence, HbA1c, Proportion achieving HbA1c <7.0%.
This study contributes evidence to
Primary intervention
Metformin + glimepiride
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
3
Evidence pairs
334
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence topic
Save evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Metformin + glimepiride → Adverse events incidence
Metformin + glimepiride → Adverse events incidence
Metformin + glimepiride → Proportion achieving HbA1c <7.0%
Metformin + glimepiride → Proportion achieving HbA1c <7.0%
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and HbA1c, Metformin Therapies and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on Metformin Therapies
Contributes to Metformin Therapies evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
2 results
2 results
2 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
Metformin Therapies appears to improve HbA1c.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Proportion achieving HbA1c <7.0%
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 13 supporting studies with generally consistent results and a positive effect signal.
Limitations
Current evidence does not show a clear benefit of Metformin + glimepiride for Adverse events incidence.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Adverse events incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
